A double blind randomised placebo controlled study using clarithromycin in the treatment of children with bronchiolitis

Status

Not yet recruiting

Phases

Unknown

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12608000456358

Enrollment

104

Registered

2008-09-15

Start date

2009-01-01

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

to see whether clarithromycin improves the clinical course of bronchiolitis requiring admission to hospital.

Interventions

clarithroymycin in the treatment of bronchiolitis. oral dose of 15 mg/kg/day for a maximum of 6 doses or until hospital discharge

Study design

Allocation

Randomised controlled trial

Primary purpose

Treatment

Eligibility

Sex/Gender

All

Age

4 Weeks to 12 Months

Healthy volunteers

Inclusion criteria

children aged 1-12 months hospitalised with bronchiolitis

Exclusion criteria

cardiac disease, cystic fibrosis, chronic lung disease, Intensive care unit admission, steroid therapy, bronchodilators within 4 hours of presentation

Outcome results